Kiniksa Pharmaceuticals announced that the US Food and Drug Administration (FDA) has approved its ARCALYST injection therapy as a first-of-its-kind treatment for adults and children 12 years and older ...

The data showed that ARCALYST treatment in the trial improved clinically meaningful outcomes associated with the significant unmet medical need in recurrent pericarditis. There were rapid and ...

The US Food and Drug Administration (FDA) has approved Kiniksa Pharmaceuticals’ interleukin-1 alpha (IL-1α) and interleukin-1 beta (IL-1β) inhibitor Arcalyst (rilonacept) for the treatment of ...

Regeneron announced that its Phase 3 study of Arcalyst (rilonacept injection) met its primary and secondary endpoints for the prevention of gout attacks. This trial, known as PRE-SURGE 1 (PREventative ...

Regeneron Pharmaceuticals of Tarrytown, N.Y., announced positive results from a second late-stage clinical trial showing that its drug Arcalyst, currently approved for a rare disease, can treat gout, ...

TARRYTOWN, N.Y., Feb. 28, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that in a second Phase 3 study (PRE-SURGE 2) in gout patients initiating allopurinol ...

- ARCALYST is the first and only FDA-approved therapy for recurrent pericarditis -- Commercial launch expected in April 2021 -- Kiniksa launches Kiniksa One Connect™ patient support program -- ...